TARO-FENOFIBRATE E TABLET
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
13-07-2020
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
FENOFIBRATE
Fáanlegur frá:
SUN PHARMA CANADA INC
ATC númer:
C10AB05
INN (Alþjóðlegt nafn):
FENOFIBRATE
Skammtar:
145MG
Lyfjaform:
TABLET
Samsetning:
FENOFIBRATE 145MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
10/30/500
Gerð lyfseðils:
Prescription
Lækningarsvæði:
FRIBIC ACID DERIVATIVES
Vörulýsing:
Active ingredient group (AIG) number: 0118895006; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2016-05-12
Vara einkenni
_Page 1 of 41_
_Pr_
_TARO-FENOFIBRATE E (Fenofibrate Tablets, Mfr. Std.) Product Monograph
_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TARO-FENOFIBRATE E
Fenofibrate Tablets, Mfr. Std.
145 mg
LIPID METABOLISM REGULATOR
Sun Pharma Canada Inc.
126 East Drive
Brampton, ON
L6T 1C1
Date of Revision:
July 13, 2020
Submission Control No: 234145
_Page 2 of 41_
_Pr_
_TARO-FENOFIBRATE E (Fenofibrate Tablets, Mfr. Std.) Product Monograph
_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
........................................................ 3
SUMMARY PRODUCT INFORMATION
..................................................................................
3
INDICATIONS AND CLINICAL USE
........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
4
WARNINGS AND PRECAUTIONS
............................................................................................
4
ADVERSE REACTIONS
..............................................................................................................
8
DRUG INTERACTIONS
............................................................................................................
12
DOSAGE AND ADMINISTRATION
........................................................................................
15
OVERDOSAGE
..........................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
17
STORAGE AND STABILITY
....................................................................................................
18
DOSAGE FORMS, COMPOSITION AND PACKAGING
....................................................... 19
PART II: SCIENTIFIC INFORMATION
..............................................................................
20
PHARMACEUTICAL INFORMATION
......
Lestu allt skjalið
